The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group for 30 years. The purpose of this grant application is to support the continued membership of the Mayo Clinic in the Eastern Cooperative Oncology Group. The goals are directed toward a greater understanding of malignancies, a better understanding of related problems in malignant diseases, development of improved treatment programs in malignant diseases, and improved patient survival in malignant diseases. Mayo Clinic has the resources, personnel, facilities, and patient population to facilitate strong contributions to the research programs of ECOG. With the continued growth and development of the Mayo medical practice, we would anticipate significant protocol entry and scientific contributions. The ECOG affiliation with its strong treatment and ancillary laboratory programs which have evolved provide major benefits to Mayo Clinic, its investigators, its affiliated regional cancer programs, and the large group of patients with malignant diseases who are involved in these research activities.
The specific aims of this grant proposal are to support the following aspects of Mayo Clinic ECOG research activities which include the following: 1.) evaluation of new protocol design and treatment regimens to provide group-wide ECOG Phase II and Phase III treatment protocols in malignant diseases; 2.) coordination of, and participation in, adjunctive laboratory-based correlative studies in association with ECOG treatment protocols in malignant diseases; 3.) development of new prognostic factors and indexes in hematologic malignancies; 4.) participation in disease-specific accrual and activities; 5.) and participation in administrative activities in ECOG.
These aims will be incorporated into a clinical trial infrastructure that is focused on institutional patient quality of care, clinical research associate (CRA) development, and faculty development. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA013650-32
Application #
6772912
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-06-01
Project End
2010-04-30
Budget Start
2004-08-11
Budget End
2005-04-30
Support Year
32
Fiscal Year
2004
Total Cost
$235,668
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Partridge, Ann H; Sepucha, Karen; O'Neill, Anne et al. (2017) Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy? Breast Cancer Res Treat 165:545-553
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726
Pine, Alexander B; Lee, Eun-Ju; Sekeres, Mikkael et al. (2017) Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 57:289-295
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828
Roberts, Kathryn G; Gu, Zhaohui; Payne-Turner, Debbie et al. (2017) High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. J Clin Oncol 35:394-401
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004

Showing the most recent 10 out of 159 publications